FBR Capital Reiterates Outperform on Cytokinetics (CYTK) Following Potential for Omecamtiv Approval
Tweet Send to a Friend
FBR Capital reiterated an Outperform rating and $24.00 price target on Cytokinetics (NASDAQ: CYTK) as COSMIC-HF results with omecamtiv mecarbil ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
